Skip to content

Design and development of a delayed-release dose-flexible matrix tablet of tolfenamic acid for potential application in cancer therapy.

Sep 2026 · International journal of pharmaceutics · pp. 127404 · 0 citations · 51 references
Medicine

Abstract

Tolfenamic acid (TFA), a Biopharmaceutics Classification System (BCS) class II drug, exhibits dissolution-limited absorption and significant gastric irritation when administered as conventional immediate-release formulations, limiting its potential for high-dose and long-term applications, including emerging anticancer indications. The present study aimed to develop a delayed-release, dose-flexible matrix tablet of TFA using enteric polymers incorporated directly into the tablet matrix, eliminating the need for external enteric coating. A 2 × 3 factorial formulation screening design was employed to systematically evaluate the influence of enteric polymers (HPMC-AS, Eudragit S100, and cellulose acetate phthalate) and diluent/binder (microcrystalline cellulose, spray-dried mannitol, and lactose monohydrate) on acid resistance and buffer-stage drug release. Tablets were prepared by wet granulation and characterized for physicochemical properties, solid-state stability, surface morphology, chemical uniformity, assay, presence of impurities, disintegration, and two-stage dissolution performance. The optimized formulation maintained complete integrity in an acidic medium for 2 h with no drug release and achieved > 96% drug release in phosphate buffer (pH 8.2) in 3 h, meeting USP dissolution criteria. Solid-state analysis confirmed preservation of the crystalline form and the absence of drug-excipient incompatibility, while stability studies under accelerated and intermediate conditions demonstrated maintained physicochemical integrity and release performance. The developed matrix system provides a cost-effective and process-efficient alternative to conventional enteric coating and supports modular dose adjustment within a single strength, offering a promising platform for delayed-release, dose-flexible oral therapy suitable for combination regimens and personalized cancer treatment strategies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.